# China NMPA Product Recall - Human Immunodeficiency Virus Antibody (HIVI1+2) Detection Reagent (Colloidal Gold Method)

Source: https://www.globalkeysolutions.net/records/china_product_recall/shanghai-rongsheng-biopharmaceutical-co-ltd/7022e8cc-105e-4e6d-a904-ff8ea94adb7d/
Source feed: China

> China NMPA product recall for Human Immunodeficiency Virus Antibody (HIVI1+2) Detection Reagent (Colloidal Gold Method) by Shanghai Rongsheng Biopharmaceutical Co., Ltd. published July 19, 2012. Recall level: Class I Recall. The National Medical Products Administration (NMPA) issued a Class I recall on July 19, 2012, for th

---

## Details

- Record Type: CHINA_PRODUCT_RECALL
- Title: Shanghai Rongsheng Biopharmaceutical Co., Ltd. is recalling its Human Immunodeficiency Virus Antibody (HIVI1+2) Test Kit (Colloidal Gold Method).
- Company Name: Shanghai Rongsheng Biopharmaceutical Co., Ltd.
- Publication Date: 2012-07-19
- Product Name: Human Immunodeficiency Virus Antibody (HIVI1+2) Detection Reagent (Colloidal Gold Method)
- Recall Level: Class I Recall
- Recall Reason: Some batches of products have low sensitivity and high false negative rate.
- Discovering Company: Shanghai Rongsheng Biopharmaceutical Co., Ltd.
- Manufacturing Company: Shanghai Rongsheng Biopharmaceutical Co., Ltd.
- Summary: The National Medical Products Administration (NMPA) issued a Class I recall on July 19, 2012, for the Human Immunodeficiency Virus Antibody (HIVI1+2) Test Kit (Colloidal Gold Method), manufactured by Shanghai Rongsheng Biopharmaceutical Co., Ltd. This serious recall was voluntarily initiated by the company after market feedback revealed significant quality issues with specific product batches (20101201 and 20110301). The main violation identified was the critical performance deficiency of low sensitivity and a high false negative rate, which means the test kits were prone to missing actual HIV infections, posing a substantial public health risk. In response, Shanghai Rongsheng Biopharmaceutical Co., Ltd. conducted an internal investigation into the affected batches and communicated directly with its customers regarding the recall. The NMPA mandated that all provincial, autonomous region, and municipal food and drug administrations enhance their supervision and management over such medical devices, reinforcing the regulatory body's commitment to product safety and efficacy.

Company: https://www.globalkeysolutions.net/companies/shanghai-rongsheng-biopharmaceutical-co-ltd/2d2ef137-4803-431a-9d71-9817c3e454f2/